Entity Common Stock, Shares Outstanding of Adaptimmune Therapeutics PLC from 11 May 2016 to 11 Aug 2025

Taxonomy & unit
dei: shares
Description
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
Summary
Adaptimmune Therapeutics PLC quarterly Entity Common Stock, Shares Outstanding in shares history and change rate from 11 May 2016 to 11 Aug 2025.
  • Adaptimmune Therapeutics PLC Entity Common Stock, Shares Outstanding for the quarter ending 11 Aug 2025 was 1,590,309,546, a 3.6% increase year-over-year.
Source SEC data
View on sec.gov
Entity Common Stock, Shares Outstanding, Quarterly (shares)
Entity Common Stock, Shares Outstanding, YoY Quarterly Change (%)

Adaptimmune Therapeutics PLC Quarterly Entity Common Stock, Shares Outstanding (shares)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2025 1,590,309,546 +55,836,876 +3.6% 11 Aug 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 1,543,391,646 +62,441,190 +4.2% 21 Mar 2025 10-K 24 Mar 2025 2024 FY
Q3 2024 1,535,299,242 +172,569,660 +13% 12 Nov 2024 10-Q 13 Nov 2024 2024 Q3
Q2 2024 1,534,472,670 +177,440,724 +13% 08 Aug 2024 10-Q 12 Aug 2024 2024 Q2
Q1 2024 1,480,950,456 +489,119,298 +49% 04 Mar 2024 10-K 06 Mar 2024 2023 FY
Q3 2023 1,362,729,582 +379,755,474 +39% 07 Nov 2023 10-Q 08 Nov 2023 2023 Q3
Q2 2023 1,357,031,946 +376,809,084 +38% 07 Aug 2023 10-Q 09 Aug 2023 2023 Q2
Q1 2023 991,831,158 +51,437,340 +5.5% 03 Mar 2023 10-K 06 Mar 2023 2022 FY
Q3 2022 982,974,108 +45,749,748 +4.9% 07 Nov 2022 10-Q 08 Nov 2022 2022 Q3
Q2 2022 980,222,862 +43,692,168 +4.7% 30 Jun 2022 10-Q 04 Aug 2022 2022 Q2
Q1 2022 940,393,818 +7,409,298 +0.79% 11 Mar 2022 10-K 14 Mar 2022 2021 FY
Q3 2021 937,224,360 +8,551,776 +0.92% 02 Nov 2021 10-Q 04 Nov 2021 2021 Q3
Q2 2021 936,530,694 +8,562,408 +0.92% 06 Aug 2021 10-Q 09 Aug 2021 2021 Q2
Q1 2021 932,984,520 +152,532,730 +20% 04 May 2021 10-Q 06 May 2021 2021 Q1
Q3 2020 928,672,584 +297,678,718 +47% 04 Nov 2020 10-Q 05 Nov 2020 2020 Q3
Q2 2020 927,968,286 +297,205,426 +47% 04 Aug 2020 10-Q 06 Aug 2020 2020 Q2
Q1 2020 780,451,790 +152,094,490 +24% 26 Feb 2020 10-K 27 Feb 2020 2019 FY
Q3 2019 630,993,866 +3,571,168 +0.57% 05 Nov 2019 10-Q 06 Nov 2019 2019 Q3
Q2 2019 630,762,860 +64,266,460 +11% 29 Jul 2019 10-Q 01 Aug 2019 2019 Q2
Q1 2019 628,357,300 +66,214,662 +12% 02 May 2019 10-Q 06 May 2019 2019 Q1
Q3 2018 627,422,698 +65,303,364 +12% 02 Nov 2018 10-Q 06 Nov 2018 2018 Q3
Q2 2018 566,496,400 +5,381,874 +0.96% 31 Jul 2018 10-Q 02 Aug 2018 2018 Q2
Q1 2018 562,142,638 +137,367,546 +32% 09 Mar 2018 10-K 15 Mar 2018 2017 FY
Q3 2017 562,119,334 +137,407,434 +32% 31 Oct 2017 10-Q 02 Nov 2017 2017 Q3
Q2 2017 561,114,526 +136,402,626 +32% 03 Aug 2017 10-Q 03 Aug 2017 2017 Q2
Q1 2017 424,775,092 +63,192 +0.02% 08 Mar 2017 10-K 13 Mar 2017 2016 FY
Q3 2016 424,711,900 10 Nov 2016 10-Q 10 Nov 2016 2016 Q3
Q2 2016 424,711,900 05 Aug 2016 10-Q 08 Aug 2016 2016 Q2
Q1 2016 424,711,900 11 May 2016 10-Q 12 May 2016 2016 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.